Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Antiobesity drugs are amazing people by how fast they melt off pounds. But it's no surprise to Richard DiMarchi.

Global Type 1 diabetes market is set to grow at a compound annual growth rate (CAGR) of 13.3 per cent from $2.2 billion in ...

Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... up at mealtimes with fast-acting insulins.

A blockbuster drug is a therapy that generates at least $1 billion in sales. Clarivate’s Drugs to Watch 2025 report includes ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Your body either doesn’t make enough insulin or can’t effectively use ... your blood sugar is checked after you fast overnight. Then you’re given a sugary drink and your blood sugar is ...

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...